C92.11
BillableChronic myeloid leukemia, BCR/ABL-positive, in remission
HCC Category Mapping
What This Code Means
This is a type of blood cancer where bone marrow produces too many abnormal white blood cells due to a specific genetic mutation (BCR/ABL), but the disease is currently in remission, meaning cancer cells are not actively growing or are undetectable.
Coding Tips
- •Ensure documentation explicitly states 'in remission' status, as this fifth character is critical for accurate coding and affects treatment planning and prognosis tracking
- •Verify the BCR/ABL-positive status is confirmed through cytogenetic or molecular testing before coding, as this distinguishes it from other myeloid leukemias and impacts targeted therapy eligibility
Clinical Significance
Chronic myeloid leukemia, BCR/ABL-positive, in remission indicates successful response to tyrosine kinase inhibitor therapy with achievement of complete cytogenetic response (CCyR) or deep molecular response. In the modern treatment era, many CML patients achieve sustained deep molecular responses, and select patients may be candidates for treatment-free remission (TKI discontinuation). Even in remission, lifelong monitoring is generally recommended.
Documentation Requirements
- ✓Documentation must confirm BCR/ABL positivity, remission status, and the level of response (complete hematologic, cytogenetic, or molecular response).
- ✓BCR-ABL1 transcript levels by quantitative PCR (IS scale) should be documented.
- ✓For patients in treatment-free remission, documentation of TKI discontinuation date and molecular monitoring frequency (monthly for first year, then quarterly) is essential.